SCYL1 and neurodegenerative disease: The literature confirmed the identified pathological paths from genetic variants to AD via brain regions: CD33 → medial temporal and hippocampus (Wang et al., 2019) → AD (Pasquini et al., 2019) and CD33 → AD (Miles et al., 2019); APP → medial and lateral temporal lobe (Huang C.C. et al., 2019) → AD (Buckner et al., 2008) and APP → AD (Zhou et al., 2011); SCYL1 → cerebellar atrophy (Schmidt et al., 2015) → AD (Gallo et al., 2017); and SCYL1 → neurodegenerative disease (Schmidt et al., 2007).